Drug Profile


Alternative Names: H-1PV; ParvOryx; parvovirus H1

Latest Information Update: 10 Dec 2015

Price : $50

At a glance

  • Originator German Cancer Research Center; University of Heidelberg
  • Developer Oryx GmbH & Co; University of Heidelberg
  • Class Antineoplastics; Oncolytic viruses
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Pancreatic cancer
  • Phase I/II Glioblastoma

Most Recent Events

  • 10 Dec 2015 H 1PV is available for licensing as of 10 Dec 2015. http://www.oryx-medicine.com/
  • 15 Oct 2015 Phase-II clinical trials in Pancreatic cancer (Metastatic disease, Inoperable/Unresectable) in Germany (Intratumoural and IV) (EudraCT2015-001119-11)
  • 01 May 2015 Oryx completes a phase I/II trial in Glioblastoma in Germany (NCT01301430)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top